Australian Clinical Labs (ACL) H2 2026 earnings summary

Executive summary

• Achieved improved underlying margins and EBIT above guidance, with a 9.4% margin and EBIT up 1.7% year-over-year, despite industry fee cuts, inflation, and low market volumes.

• Returned AUD 47 million ($47.1m, 10.7% of market cap) to shareholders via dividends and buybacks, maintaining a strong balance sheet and ongoing repurchase plans.

• Business redesign, operational initiatives, and innovation set a foundation for sustainable earnings growth as volumes recover.

• Leadership transition with a new CEO, maintaining strategic direction and disciplined execution.

Financial highlights

• FY 2026 revenue was AUD 736 million ($735.8m), down year-over-year due to market softness and Medicare fee cuts.

• Underlying EBIT reached AUD 69.2 million (9.4% margin), up 1.7% from FY 2025; underlying NPAT was AUD 35.5 million, up 4.3% year-over-year.

• Underlying EPS rose 8.5%; reported NPAT was AUD 24 million, with the variance explained by one-off items.

• Free cash flow was AUD 64.7 million, down from the prior year, but cash conversion remained strong at 119.2% of EBITDA.

• Net debt at year-end was AUD 37.4 million, or 0.5x underlying EBITDA.

Outlook and guidance

• FY 2027 revenue guidance: AUD 745–765 million ($745m–$765m); underlying EBIT: AUD 67–73 million; EBIT margin: 9–9.5%.

• Guidance assumes modest market growth, continued wage pressure, and benefits from ongoing initiatives (billing, AI, Lab of the Future).

• Strategic initiatives to offset wage increases and gender undervaluation costs, with focus on upfront billing, price increases, and automation.

• No rapid market recovery assumed; focus remains on controllable initiatives and margin stability.

• Share buybacks to continue, subject to capital needs and investment priorities.